Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2012
10/25/2012US20120269845 Opthalmic composition containing xanthan gum and amino acid
10/25/2012US20120269840 Expression of hiv polypeptides and production of virus-like particles
10/25/2012US20120269831 Substituted pyrido[2,3-d]pyrimidin-7(8h)-ones and therapeutic uses thereof
10/25/2012US20120269815 Neurotrophins and uses thereof
10/25/2012US20120269810 Methods and compositions for panic disorders
10/25/2012US20120269804 Substituted benzosulphonamides
10/25/2012US20120269803 Substituted benzosulphonamides
10/25/2012US20120269802 Treatment And Prognosis With Thalidomide In Multiple Myeloma Based on Karyotyping And Gene Expression Profiling
10/25/2012US20120269800 Anti-neoplastic compositions comprising extracts of black cohosh
10/25/2012US20120269798 Enhancement of regeneration by modulation of notum activity
10/25/2012US20120269797 Method for inhibiting the maturation of dendritic cells
10/25/2012US20120269796 Method for Enhancing Pancreatic Beta Cell Proliferation, Increasing Serum Insulin Concentration, Decreasing Blood Glucose Concentration And Treating And/Or Preventing Diabetes
10/25/2012US20120269793 Phytoestrogenic formulations for alleviation or prevention of hair loss
10/25/2012US20120269792 Eutectic-based self-nanoemulsified drug delivery system
10/25/2012US20120269772 Lipid depot formulations
10/25/2012US20120269771 Sialochimeric compounds
10/25/2012US20120269769 Hepatitis C Inhibitor Compounds
10/25/2012US20120269768 Antiviral product
10/25/2012US20120269767 Treatment of Neurodegenerative Diseases
10/25/2012US20120269766 Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus
10/25/2012US20120269762 Causal therapy of diseases or conditions associated with cns or pns demyelination
10/25/2012US20120269761 Biodegradable elastomers
10/25/2012US20120269760 Eye Drops
10/25/2012US20120269740 Use of benzyloxy-ethylamine derivatives as a preservative, preservation method, and compositions
10/25/2012US20120269738 Imaging Beta-Amyloid Peptides and Inhibition of Beta-Amyloid Peptide Aggregation
10/25/2012US20120269725 Targeted radiolabeled compounds and their use for the treatment and diagnosis of cancer
10/25/2012US20120269722 Chemoembolisation
10/25/2012DE102011007891A1 New ring-fused 4-aminopyrimidine compounds are guanylate cyclase stimulators useful to treat and/or prevent e.g. heart failure, angina pectoris, hypertonia, pulmonary hypertonia, ischemia, vascular disease and renal insufficiency
10/25/2012DE102011007890A1 New fluoroalkyl-substituted pyrazolopyridine compounds are soluble guanylate cyclase stimulators, useful to treat e.g. heart disease, angina pectoris, hypertension, pulmonary hypertension, ischemia, vascular disease or renal insufficiency
10/24/2012EP2514824A2 Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
10/24/2012EP2514823A2 Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
10/24/2012EP2514822A1 Anti-thrombosis aptamers and method for stabilizing the structure thereof
10/24/2012EP2514759A1 Triterpene derivative, and prophylactic or therapeutic agent for chronic hepatitis c
10/24/2012EP2514756A1 Novel compounds having inhibitory activity against sodium-dependant glucose transporter
10/24/2012EP2514754A1 6,7-dihydro-[1,3,4]thiadiazolo-[3,2-a][1,3]diazepin derivatives and pharmaceutical composition containing the same as neuromuscular blocker or skeletal muscle relaxant, and method for the preparation
10/24/2012EP2514753A1 6,7-Dihydro-[1,3,4]thiadiazolo-[3,2-a][1,3]diazepin derivatives and pharmaceutical compositions containing the same as hypnotic or anesthetic agent and method for their preparation
10/24/2012EP2514752A1 Epothilone compounds, preparation method and use thereof
10/24/2012EP2514751A1 Azaindazoles useful as inhibitor of kinases
10/24/2012EP2514750A1 Bromo-phenyl substituted thiazolyl dihydropyrimidines
10/24/2012EP2514749A1 Oxadiazole derivative having endothelial lipase inhibitory activity
10/24/2012EP2514748A1 2,4-diaminoquinazolines for spinal muscular atrophy
10/24/2012EP2514747A1 Substituted aminothiazine derivative
10/24/2012EP2514746A1 Stable crystal of 4-oxoquinoline compound
10/24/2012EP2514745A1 GPR120 receptor agonists and uses thereof
10/24/2012EP2514743A1 Immunosuppressant Compounds and Compositions
10/24/2012EP2514742A2 Orally bioavailable cafeic acid related anticancer drugs
10/24/2012EP2514739A1 Substituted beta-phenyl-alpha-hydroxy propanoic acid, synthesis method and use thereof
10/24/2012EP2514483A1 Adjuvant immunotherapy for the preventive, curative or palliative treatment of chronic systemic diseases such as cancer, of clinical manifestations associated with these diseases, such as cachexia, and remedying adverse effects of drugs and treatments, such as immunodepression, neutropenia and lymphocytopenia, comprising the association or combination of a specially selected biological response modifier and other antineoplastic compounds and/or other treatments
10/24/2012EP2514441A1 Passive solid tumor targeting anticancer prodrug and preparation method thereof
10/24/2012EP2514440A1 Transdermal preparation containing basic anti-inflammatory agent
10/24/2012EP2514429A1 Antioxidant
10/24/2012EP2514426A1 Compounds having anti-inflammatory activity
10/24/2012EP2514425A1 Composition containing protopanaxatriol and protopanaxadiol
10/24/2012EP2514424A1 Piroxicam-containing endermic preparation
10/24/2012EP2514423A2 Method of treatment of age-related macular degeneration (AMD)
10/24/2012EP2514422A1 Elution-stabilized preparation
10/24/2012EP2514421A1 Composition comprising torasemide
10/24/2012EP2514420A2 Use of rapamycin for the treatment or prevention of age-related macular degeneration
10/24/2012EP2514419A1 Felbinac-containing transdermal absorption preparation
10/24/2012EP2514418A1 Traditional chinese drug comprising danshen extracts and sanqi extracts and use thereof
10/24/2012EP2514417A2 Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
10/24/2012EP2514416A1 Transdermally absorbed preparation of anti-dementia drug
10/24/2012EP2514415A1 Transdermally absorbed preparation of anti-dementia drug
10/24/2012EP2514414A1 Transdermally absorbed preparation of anti-dementia drug
10/24/2012EP2514413A1 Controlled-Release Gliclazide Formulations
10/24/2012EP2514409A1 Topical pharmaceutical compositions of nimesulide and methylsulfonylmethane
10/24/2012EP2514402A1 Prophylactic or ameliorating agent fo pigmentation
10/24/2012EP2513343A1 Methods and compositions for treating inflammation of skin
10/24/2012EP2513334A1 Dicer substrate agents and methods for the specific inhibition of gene expression
10/24/2012EP2513310A2 Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
10/24/2012EP2513308A1 Modulation of pilr to treat immune disorders
10/24/2012EP2513307A1 Micro-rna regulation in ischemia and ischemia-reperfusion injury
10/24/2012EP2513298A2 Beta-cell replication promoting compounds and methods of their use
10/24/2012EP2513225A1 Local delivery of drugs from self assembled coatings
10/24/2012EP2513131A1 Novel 3´-deoxy-3´-methylidene- -l-nucleosides
10/24/2012EP2513128A2 Mannose derivatives as antagonists of bacterial adhesion
10/24/2012EP2513121A1 Prostate specific membrane antigen inhibitors
10/24/2012EP2513119A1 3,4,4A,10B-TETRAHYDRO-1H-THIOPYRANO-[4, 3-c]ISOQUINOLINE DERIVATIVES
10/24/2012EP2513117A1 Bicyclic thiazoles as allosteric modulators of mglur5 receptors
10/24/2012EP2513115A1 Tricyclic antibiotics
10/24/2012EP2513114A1 Pyrrolo[2,3-d]pyrimidine compounds
10/24/2012EP2513113A1 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
10/24/2012EP2513112A2 Method for late introduction of the (8r)-hydroxyl group in carbapenem beta-lactam antibiotic synthesis
10/24/2012EP2513111A1 Mk2 inhibitors
10/24/2012EP2513110A1 1, 7 - diazacarbazoles and their use in the treatment of cancer
10/24/2012EP2513109A1 Heterocyclic compounds and their uses
10/24/2012EP2513108A1 Novel (heterocycle/condensed piperidine)-(piperazinyl)-1-alcanone or (heterocycle/condensed pyrrolidine)-(piperazinyl)-1-alcanone derivatives, and use thereof as p75 inhibitors
10/24/2012EP2513107A1 Heteroaromatic phenylimidazole derivatives as pde10a enzyme inhibitors
10/24/2012EP2513106A1 Heteroaromatic aryl triazole derivatives as pde10a enzyme inhibitors
10/24/2012EP2513105A1 2-arylimidazole derivatives as pde10a enzyme inhibitors
10/24/2012EP2513104A1 Anti parasitic dihydroazole compounds and compositions comprising same
10/24/2012EP2513103A1 Azaindole glucokinase activators
10/24/2012EP2513102A1 Ethynyl derivatives
10/24/2012EP2513101A1 Novel solvates of methyl{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate
10/24/2012EP2513100A1 New phenylhydrazone derivatives and their use as pharmaceuticals
10/24/2012EP2513098A1 Aminopyrimidines as syk inhibitors
10/24/2012EP2513097A1 Diazabicyclononyl oxadiazole compounds and their use as nicotinic acetylcholine receptor modulators
10/24/2012EP2513096A1 Substituted aminothiazolone indazoles as estrogen related receptor-a modulators
10/24/2012EP2513095A1 Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists
10/24/2012EP2513094A2 Salts and crystalline forms of a factor xa inhibitor
1 ... 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 ... 7860